Skip to content

The Effect of Creatine on Muscle Loss

The Effect of Creatine Supplementation on Muscle Loss During Immobilisation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01894737
Acronym
CML
Enrollment
30
Registered
2013-07-10
Start date
2013-10-31
Completion date
2015-04-30
Last updated
2015-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Loss

Brief summary

The primary aim of this study is to determine the effect of creatine supplementation on muscle mass loss during short-term immobilisation in healthy, young people.

Detailed description

Seven days of one-legged knee immobilisation in young subjects with creatine or Placebo supplementation. A randomly selected leg is immobilized for seven days. Muscle mass and strength will be determined and muscle biopsies will be collected before and immediately after immobilisation. A week after the cast is removed we will assess any differences in recovery between intervention groups.

Interventions

OTHERPlacebo supplementation

Seven days of one-legged knee immobilisation with placebo supplementation

Seven days of one-legged knee immobilisation with creatine supplementation.

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Male * Aged from 18-35 years * 18.5 \< BMI \< 30 kg/m2

Exclusion criteria

* (Family) history of thrombosis * Smoking * Recent surgery * Performing regular resistance training more than once per week in the past year * Any back/leg/knee/shoulder complaints which may interfere with the use of crutches * Current systemic use of corticosteroids, growth hormone, testosterone, immunosuppressants or insulin * All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis) * Use of anti-coagulants * Pre-existing renal disease or those with a potential risk for renal dysfunction (diabetes, hypertension, reduced glomerular filtration rate)

Design outcomes

Primary

MeasureTime frameDescription
change in quadriceps muscle cross-sectional area (CSA)Before and after 1 week of immobilisation, and after 1 week of recoveryimmediately before and after 1 week of immobilisation, and after 1 week recovery, quadriceps CSA will be assessed

Secondary

MeasureTime frameDescription
change in muscle fiber type specific CSABefore and after 1 week of immobilisation, and after 1 week of recoveryimmediately before and after 1 week of immobilization, and after 1 week of natural recovery
change in muscle strengthbefore and after 1 week of immobilisation, and after 1 week of recoveryimmediately before and after 1 week of immobilization, and after 1 week of natural recovery, one-repetition maximum (1RM) muscle strength will be assessed

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026